The topline findings from TRIUMPH-2 and TRIUMPH-3 suggest that retatrutide has the potential to deliver substantial weight reduction alongside improvements in glycemic control and several cardiometabolic risk markers in these higher-risk populations
A responsible plan may include adequate protein intake, resistance training, walking or other appropriate activity, body composition tracking when available, lab monitoring, gradual dose escalation when appropriate, nutrition support during appetite reduction, hydration and electrolyte guidance, monitoring fatigue or excessive appetite suppression, and evaluation for hormone, thyroid, or nutrient issues when relevant
Heres what to know: What is retatrutide
Researchers continue to investigate: Triple hormone agonists Oral GLP-1 medications Combination therapies Muscle-preserving weight loss treatments These advancements are helping reshape the future of obesity medicine and may expand personalized treatment options for patients in the years ahead
NEJM 2023: 10.1056/NEJMoa2301972 Phase 2 dose-response (1, 4, 8, 12 mg arms, 48 wk, non-diabetic obesity)
Pi represents inorganic phosphoric acid
